Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Aspirin, PIK3CA mutation, and colorectal-cancer survival.

Ogino S, Liao X, Chan AT.

N Engl J Med. 2013 Jan 17;368(3):289-90. doi: 10.1056/NEJMc1214189. No abstract available.

2.

Aspirin, PIK3CA mutation, and colorectal-cancer survival.

Sahin IH, Garrett C.

N Engl J Med. 2013 Jan 17;368(3):289. doi: 10.1056/NEJMc1214189#SA2. No abstract available.

PMID:
23323915
3.

Aspirin, PIK3CA mutation, and colorectal-cancer survival.

Viúdez A, Hernandez I, Vera R.

N Engl J Med. 2013 Jan 17;368(3):289. doi: 10.1056/NEJMc1214189#SA1. No abstract available.

PMID:
23323914
4.

Aspirin--from prevention to targeted therapy.

Pasche B.

N Engl J Med. 2012 Oct 25;367(17):1650-1. doi: 10.1056/NEJMe1210322. No abstract available.

PMID:
23094728
5.

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S.

N Engl J Med. 2012 Oct 25;367(17):1596-606. doi: 10.1056/NEJMoa1207756.

6.

Potential biomarker for aspirin use in colorectal cancer therapy.

Langley RE, Rothwell PM.

Nat Rev Clin Oncol. 2013 Jan;10(1):8-10. doi: 10.1038/nrclinonc.2012.216. Epub 2012 Dec 4.

PMID:
23207797
7.

Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.

Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT.

Oncogene. 2014 Jun 5;33(23):2949-55. doi: 10.1038/onc.2013.244. Epub 2013 Jun 24. Review.

8.

Aspirin, the new targeted therapy in colorectal cancer.

Fuchs CS.

Clin Adv Hematol Oncol. 2014 Mar;12(3):186-9. No abstract available.

PMID:
24927268
9.

Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!

Fuchs CS, Ogino S.

J Clin Oncol. 2013 Dec 1;31(34):4358-61. doi: 10.1200/JCO.2013.52.0080. Epub 2013 Oct 28. No abstract available.

10.

[Aspirin and PIK3CA mutation in colorectal cancer].

Kirstein MM, Vogel A.

Z Gastroenterol. 2014 Mar;52(3):306-7. doi: 10.1055/s-0033-1356386. Epub 2014 Mar 12. German. No abstract available.

PMID:
24622874
11.

Multiplexed assays for detection of mutations in PIK3CA.

Board RE, Thelwell NJ, Ravetto PF, Little S, Ranson M, Dive C, Hughes A, Whitcombe D.

Clin Chem. 2008 Apr;54(4):757-60. doi: 10.1373/clinchem.2007.098376.

12.

Aspirin extends life of some patients with colorectal cancer.

Printz C.

Cancer. 2013 Feb 1;119(3):472-3. doi: 10.1002/cncr.27961. No abstract available.

13.

Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.

Hawkes E, Cunningham D.

J Clin Oncol. 2010 Oct 1;28(28):e529-31; author reply e532-e533. doi: 10.1200/JCO.2010.29.5626. Epub 2010 Aug 2. No abstract available.

14.

Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.

Smith CJ, McKay GA, Fisher M.

Int J Clin Pract. 2008 May;62(5):810-5. doi: 10.1111/j.1742-1241.2008.01726.x. Epub 2008 Mar 25. Review.

PMID:
18373616
15.

Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.

Arber N, Spicak J, Rácz I, Zavoral M, Breazna A, Gerletti P, Lechuga MJ, Collins N, Rosenstein RB, Eagle CJ, Levin B.

Am J Gastroenterol. 2011 Jun;106(6):1135-46. doi: 10.1038/ajg.2011.116. Epub 2011 Apr 19.

PMID:
21503000
16.

Functional analysis of PIK3CA gene mutations in human colorectal cancer.

Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, Asaoka Y, Matsumura M, Kawabe T, Omata M.

Cancer Res. 2005 Jun 1;65(11):4562-7.

17.

Study finds that aspirin improves survival after colon cancer diagnosis.

Kmietowicz Z.

BMJ. 2014 Mar 31;348:g2476. doi: 10.1136/bmj.g2476. No abstract available.

PMID:
24691102
18.

Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.

Benamouzig R, Uzzan B, Martin A, Deyra J, Little J, Girard B, Chaussade S; APACC Study Group.

Gut. 2010 May;59(5):622-9. doi: 10.1136/gut.2008.175406.

PMID:
20427397
19.

Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.

Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC.

Clin Chim Acta. 2012 Oct 9;413(19-20):1605-11. doi: 10.1016/j.cca.2012.04.029. Epub 2012 May 8.

PMID:
22579930
20.

PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.

Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, Inazawa J.

Cancer Sci. 2006 Dec;97(12):1351-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk